Efficacy and Safety of Cream Containing Fig Extract in Subacute and Chronic Eczematous Dermatitis Volunteers

NCT07867249 | Not Yet Recruiting

• 1 other identifier: Oh013-69
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to evaluate the efficacy and safety of a cream containing fig extract in volunteers with subacute and chronic eczematous dermatitis. The affected area of subacute and chronic eczematous dermatitis in each participant will be equally divided into two sections (left and right) using block randomization. One section (Area A) will receive the fig extract cream, while the other section (Area B) will receive a placebo cream as the control. All study assessments, including clinical assessments, skin parameter measurements, patient-reported outcomes, and adverse event assessments, will be performed at baseline and at 1, 2, and 3 weeks after treatment initiation.

Conditions

Subacute and Chronic Eczematous Dermatitis Volunteers

Keywords

dermatitis

Outcome Measures

Primary Outcomes (1)

• The severity of subacute and chronic eczematous dermatitis

  The severity of subacute and chronic eczematous dermatitis will be assessed using the SCORAD Index. The SCORAD Index ranges from 0 to 103, with higher scores indicating greater severity of eczematous dermatitis.

  3 weeks

Secondary Outcomes (10)

• Eczema Area and Severity Index (EASI)

  3 weeks

• Area of dermatitis

  3 weeks

• Erythema level

  3 weeks

• Melanin level

  3 weeks

• Skin hydration level

  3 weeks

Study Arms (2)

Fig extract cream

EXPERIMENTAL

Apply the assigned cream to the designated areas, twice daily, in the morning and evening, for 3 weeks.

Other: Fig extract cream

Placebo cream

PLACEBO COMPARATOR

Apply the assigned cream to the designated areas, twice daily, in the morning and evening, for 3 weeks.

Other: Placebo cream

Interventions

Fig extract cream OTHER

Fig extract cream

Fig extract cream

Placebo cream OTHER

Placebo cream

Placebo cream

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female participants aged 18 years or older.
• Have subacute or chronic eczematous dermatitis greater than 6.25 cm²
• Have SCORAD Index score of less than 50, indicating mild to moderate dermatitis.
• Able to read and write.

You may not qualify if:

• Allergic to fig extract
• Have dermatitis on face, genital area, palms, or soles.
• Used topical medications for itching or oral corticosteroids within 2 weeks
• Ppregnant or breastfeeding
• Participating in other clinical research studies

Sponsors & Collaborators

• Chulalongkorn University: lead

MeSH Terms

Conditions

Dermatitis

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Pornanong Aramwit, Professor

CONTACT

+66899217255; aramwit@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: October 5, 2026
• First Posted: October 9, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 31, 2027
• Last Updated: October 9, 2026

Record last verified: 2026-10

Data Sharing

• IPD Sharing: Will not share